Study numberTumour typeStatusPhaseDetailsContact
1.2021Any Anthracycline sensitive cancer which has an injectable tumourOpen and recruiting1SHASQI SQ3370-001: Open-Label Study of SQ3370 in Patients with Advanced Solid Tumours Ph: 08 8359 2565 Fax: 08 7123 6170
2.2021Early stage Breast cancer (ER positive, Her2 neg)- for hormone blockade +/- GiredestrantOpen and recruiting3LiDERA GO42784: Randomized, open-label, study evaluating the efficacy and safety of adjuvant Giredestrant compared with physician’s choice of adjuvant endocrine monotherapy in patient with Estrogen receptor positive, HER2 negative Early Breast Ph: 08 8359 2565 Fax: 08 7123 6170
3.2021Metastatic Prostate cancer - which is hormone responsiveOpen and recruiting3ARANOTE 21140: Randomised, placebo controlled, double blind study of Darolutamide plus androgen deprivation therapy (ADT) VS ADT in subject with metastatic hormone sensitive prostate cancer (mHSPC) Ph: 08 8359 2565 Fax: 08 7123 6170
4.2022Breast Cancer (Her2 positive) and any Her2 positive cancerOpen and recruiting1MT5111 01-MT-5111: A Phase 1b open-label, multicenter dose escalation and expansion study of MT-5111 (HER2 blockade) in subjects with previously treated advanced HER2-positive solid Ph: 08 8359 2565 Fax: 08 7123 6170
5.2022Metastatic Breast cancer - ER/PR positive, Her2 negative - after prior hormone blockadeOpen and recruiting1Olema OP-1250-001: A Phase I/II Open-label, Multicenter, Dose Escalation and Dose Expansion Study of OP-1250 monotherapy in adult subjects with advanced and/or metastatic Hormone Receptor (HR)-positive, HER2-negative breast Ph: 08 8359 2565 Fax: 08 7123 6170
6.2022Metastatic Lung cancer - second line or moreOpen and recruiting3Beigene BGB-A317-Sitravatinib-301: A Randomized Phase 3 Study of Tislelizumab in Combination With Sitravatinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Progressed on or After Platinum-Based Chemotherapy and Anti-PD-(L)1 Ph: 08 8359 2565 Fax: 08 7123 6170
7.2022Metastatic Breast cancer (ER positive, Her2 neg - after first line hormone blockadeOpen and recruiting3Ember: J2J-OX-JZLC LY3484356 vs Investigator’s Choice of Endocine Therapy in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer, Previously Treated with Endocrine Ph: 08 8359 2565 Fax: 08 7123 6170
8.2022Metastatic Prostate cancer - hormone resistantOpen and recruiting1PCUR: 101-003: PCUR-101 in Combination with Androgen Directed Therapy in the Treatment of Patients with Metastatic Castration-Resistant Prostate Ph: 08 8359 2565 Fax: 08 7123 6170
9.2022Early Stage Breast Cancer - Triple negative with (Her2 1+/2+, ER-PR-)Open and recruiting2PN-301-21: Adjuvant Therapeutic Cancer Vaccine in Patients with Breast Ph: 08 8359 2565 Fax: 08 7123 6170
10.2022Metastatic triple negative Breast cancer - first lineOpen and recruiting2GS-US-586-6144: Magrolimab in Combination with Nab-Paclitaxel or Paclitaxel versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients with Metastatic Triple-Negative Breast Ph: 08 8359 2565 Fax: 08 7123 6170


Clinical trials are a critical bridge between research discovery and improved treatment and care.

Clinical trials assess the success rate of treatments in humans. Access to research discoveries mean cancer patients can participate in cutting-edge treatments and contribute to learnings.

The CRSA alliance is developing programs to address the areas of greatest need and significant gaps in clinical trial activity.

The multi-pronged approach will provide cohesive delivery of:

  • increased clinical trial capability to underserved areas
  • broadened clinical trial access to patients across Victoria
  • advanced metrics to progress measurement and evaluation of clinical trials



See RESOURCES – Clinical Trials